---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-117245"
form_type: "8-K"
ticker: "CTMX"
cik: "0001501989"
company_name: "CytomX Therapeutics, Inc."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-21T23:30:23.600370+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# CytomX Q1 revenue $50.9M; CX-2051 Phase 1 shows 28% ORR in advanced CRC

## Summary
- Q1 revenue $50.9M (up from $41.5M); operating expense $28.3M; cash $79.9M.
- CX-2051 Phase 1: 28% ORR (5/18 confirmed PRs), 94% DCR, median PFS 5.8 months in advanced CRC.
- Dose expansions started at 7.2, 8.6, 10 mg/kg Q3W; Phase 2 planned 1H 2026.
- Astellas milestone $5M; cash runway into Q2 2026.
- CX-801 Phase 1a data in melanoma expected 2H 2025.

## SEC filing metadata
- accession: 0001193125-25-117245
- form_type: 8-K
- ticker: CTMX
- cik: 0001501989
- company_name: CytomX Therapeutics, Inc.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501989/000119312525117245/0001193125-25-117245-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501989/000119312525117245/d23036d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-117245
- JSON: https://secwatch.observer/filing/0001193125-25-117245.json
- Plain text: https://secwatch.observer/filing/0001193125-25-117245.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.